EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Spacer‐Complementary Single‐Stranded DNA Oligonucleotides Can Serve as Target‐Specific Inhibitors in CRISPR/Cas9 Systems

Ruiying Han, Xiang Gao, Yiqi Qi, XiaoDan Lu, Xiaoli Wang, Xiaochuan Tang

Cell Biochemistry and Function · 2025-06 · 43 (6)

DOI: 10.1002/cbf.70088 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT The continuous expression of the CRISPR/Cas system in organisms can lead to various potential issues. Some anti‐CRISPR strategies have been developed to achieve precise control over CRISPR/Cas, yet these strategies are predominantly protein‐based, with the most commonly used anti‐CRISPR (Acr) proteins lacking sufficient target specificity. However, in this study, we designed a single‐stranded DNA (ssDNA) inhibitor that was complementary to the spacer region on the guide RNA, operating at the nucleic acid level. We demonstrated that this method effectively inhibits the cleavage activity of Cas9‐sgRNA ribonucleoprotein (RNP) in a target‐specific manner through in vitro cleavage experiments. Furthermore, we explored the binding position and effective length of this inhibitory ssDNA, finding that its inhibitory effect was significantly reduced when the length of continuous complementarity with the 5′ end of the spacer was less than 7nt. The truncated ssDNA also showed potential in reducing off‐target effects. Moreover, we applied nucleic acid inhibitors to embryos via microinjection, and gene editing activity was significantly reduced, as evidenced by a decrease in the mosaicism rate of mouse embryos undergoing normal gene editing from (84.4 ± 4.4) % to 0%. Our study introduces a convenient and target‐specific nucleic acid inhibitor capable of achieving precise regulation of gene editing.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →